Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 1995 Apr;70(4):227-30.
doi: 10.1007/BF01700380.

Leukocytoclastic vasculitis and long-term remission in a patient with secondary AML and post-remission treatment with low-dose interleukin-2

M Engelhardt  1 , J A Rump, U Hellerich, R Mertelsmann, A Lindemann
Affiliations
Case Reports

Leukocytoclastic vasculitis and long-term remission in a patient with secondary AML and post-remission treatment with low-dose interleukin-2

M Engelhardt et al. Ann Hematol. 1995 Apr.

Abstract

Interleukin-2 (IL-2) has been licensed for the treatment of renal cell carcinoma and is currently being evaluated as a therapeutic agent in hematological malignancies. It is associated with a variety of side effects due to induction of a nonspecific inflammatory response. However, phenomena of autoimmunity have also been reported. Here we describe a patient with secondary acute myeloid leukemia who developed a leukocytoclastic vasculitis during long-term post-remission treatment with very low doses of IL-2.

PubMed Disclaimer

References

    1. Intensive Care Med. 1993;19 Suppl 1:S19-28 - PubMed
    1. J Immunol. 1987 Apr 15;138(8):2718-27 - PubMed
    1. N Engl J Med. 1986 Aug 21;315(8):488-95 - PubMed
    1. Ann Intern Med. 1988 Jun;108(6):909 - PubMed
    1. Am J Med. 1992 Jun;92(6):693-7 - PubMed

Publication types

MeSH terms

LinkOut - more resources